Who is sponsoring NCT04915313?

NCT04915313 is sponsored by Capital Medical University.

What drugs are being tested in NCT04915313?

Interventions in NCT04915313: Remote ischemic conditioning (RIC), Sham remote ischemic conditioning (Sham-RIC).

What condition does NCT04915313 study?

NCT04915313 studies Hypertension,Essential, Prehypertension.

Is NCT04915313 still recruiting?

NCT04915313 is currently completed. Last updated 10 November 2022.

Last reviewed 2022-11-10 · How we verify

NCT04915313

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Antihypertensive Effect of Remote Ischemic Conditioning (RIC-HTN).

Completed NA Last updated 10 November 2022

What this trial tests

NA trial testing Remote ischemic conditioning (RIC) in Hypertension,Essential in 95 participants. Completed in 1 August 2022.

Timeline

15 June 2021

Primary endpoint
10 June 2022

1 August 2022

Quick facts

Lead sponsor	Capital Medical University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	95
Start date	15 June 2021
Primary completion	10 June 2022
Estimated completion	1 August 2022
Sites	3 locations across China

Drugs / interventions tested

Remote ischemic conditioning (RIC)
Sham remote ischemic conditioning (Sham-RIC)

Conditions studied

Hypertension,Essential — all drugs for Hypertension,Essential →
Prehypertension — all drugs for Prehypertension →

Sponsor

Capital Medical University

Who can join

Adults 50 to 80, any sex, with Hypertension,Essential or Prehypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to further reveal the antihypertensive effect of LRIC and explore its potential mechanisms.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Chronic Remote Ischemic Conditioning on Mild Hypertension in the Absence of Antihypertensive Medication: A Multicenter, Randomized, Double-Blind, Proof-of-Concept Clinical Trial.
Guo W, Zhao W, Li D, Jia H, et al · · 2023 · cited 9× · PMID 37035920 · DOI 10.1161/hypertensionaha.122.20934

Verify or expand the search:

Other trials of Remote ischemic conditioning (RIC)

Trials testing the same drug.

NCT05289518 — Remote Ischemic Conditioning for the Treatment of Stroke-related Insomnia · NA · unknown

Other recruiting trials for Hypertension,Essential

Currently open trials in the same condition.

NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
NCT06205628 — Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension · Phase 1 · active not recruiting
NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting
NCT04625569 — Genetic of Response to Acute Saline Load Test in Hypertension (Naload) · recruiting

Other Capital Medical University trials

Trials by the same sponsor.

NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04915313 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
Last refreshed: 10 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04915313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing